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The histone deacetylase inhibitor trichostatin A (TSA) has been previously shown to block cellular growth in G2 and induce apoptosis in
human pancreatic cancer cell lines. In order to better understand this phenomenon, we have analyzed the gene expression profiles in PaCa44
cells after treatment with TSA using microarrays containing 22,283 probesets. TSAwas found to cause both the induction and repression of a
large number of genes, although the number whose expression was up-regulated was greater than the number of genes that were down-
regulated. When a threshold value of 3 was used as a cutoff level, a total of 306 (3.4%) of the detectable genes had altered expression. When
categorized according to cellular function, the differentially expressed genes were found to be involved in a wide variety of cellular processes,
including cell proliferation, signaling, regulation of transcription, and apoptosis. Moreover, Sp1/Sp3 transcription factor binding sites were
significantly more abundant among TSA-induced genes. One prominent feature was the increased ratio between the levels of expression of
pro-apoptotic (BIM) and anti-apoptotic (Bcl-XL and Bcl-W) genes. This result was confirmed in eight additional pancreatic cancer cell lines
after treatment with TSA, suggesting that this event may be a strong determinant for the induction of apoptosis by TSA.
D 2004 Elsevier B.V. All rights reserved.
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Although several common molecular alterations have
been identified as key players in the oncogenesis and
progression of primary pancreatic adenocarcinoma, includ-
ing the K-ras, p53, p16, DPC4, and FHIT genes [1–3],
current therapeutic and diagnostic strategies have gained
little and prognosis remains dismal with a 5-year survival of
less than 5%.
It is now well accepted that epigenetic mechanisms play
a key role in the pathogenesis of cancer [4]. DNA0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2004.07.001
* Corresponding author. Tel.: +39 045 802 7017; fax: +39 045 802
7136.
E-mail address: aldo.scarpa@univr.it (A. Scarpa).methylation has been widely studied by a variety of
experimental approaches, and molecules that interfere with
DNA methylation have also been evaluated in clinical trials
in both solid and hematologic malignancies [5,6]. Far less
attention has been paid to histone acetylation, although
multiple studies have demonstrated that histone acetylation,
likewise, has an important role in the regulation of gene
expression [7–9]. Histone acetylation is regulated by the
activities of histone acetyl-transferase (HAT) and histone
deacetylase (HDAC). Higher levels of histone acetylation
have been associated with transcriptional activation due to
the decreased interaction between histones and DNA, while
hypoacetylated histones are generally associated with tran-
scriptionally inactive chromatin. A role for histone acetyla-
tion and deacetylation in control of cell growth andta 1693 (2004) 167–176
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importantly, inhibitors of HDAC have been suggested to
be applicable in the clinical treatment of human malignan-
cies [11,12].
In recent years, a variety of compounds that inhibit
HDAC have been identified, which cause growth arrest,
differentiation and/or apoptotic cell death, including trichos-
tatin A (TSA) [13,14]. Furthermore, these agents display
selective toxicity to cancer cell lines [15,16] and also reduce
growth of neoplastic cells in animal models at nontoxic
doses [17]. Moreover, it has been reported that TSA can
modulate gene expression during mouse embryogenesis
with little or no apparent cytotoxic effects [18].
HDAC inhibitors may also have utility in the clinical
management of pancreatic cancer. Recently, the HDAC
inhibitor CI-994 was used in a randomized clinical trial in
patients with advanced pancreatic cancer (cited in Ref.
[19]). Disappointingly, there was no increase in survival
when CI-994 was given alone or in combination with
gemcitabine. However, it has been shown that CI-994 has
a predominantly cytostatic effect due to its ability to arrest
the cell cycle in the G1 phase [20]. From our recent
studies, it is clear that TSA has a mechanism of action
different from CI-994 in that it arrests cellular growth in
G2 and induces apoptosis [14]. In fact, the possibility that
different HDAC inhibitors may have diverse mechanisms
of action has recently been reinforced by characterization
of three different molecules that all induce cell death
through an intrinsic apoptotic pathway as for TSA [21].
Nonetheless, a recent microarray analysis has hinted on the
possibility that at least some HDAC inhibitors may have
similar mechanisms of action, as hierarchical clustering of
expression profiles demonstrated a greater similarity
between suberoylanilide hydroxamic acid and TSA with
respect to MS-27-275 [22]. At any rate, it has been
suggested that the action of HDAC inhibitors on gene
expression is restricted to a relatively small number of
genes including BCL2-related pathways [21,23] and the
molecular mechanisms of action of HDAC inhibitors
remain poorly understood.
The continuing study of the effects of histone acetylation
as related to gene expression is fundamental in order to
identify possible therapeutic targets, given the antiprolifer-
ative effects of TSA and other HDAC inhibitors. To date,
only a limited number of studies have been performed
examining variations in gene expression induced by TSA in
human tumor cells [22,24–26]. To better understand its
mechanism of action, we have compared the gene expres-
sion profiles of the pancreatic cancer cell line PaCa44 before
and after treatment with the HDAC inhibitor TSA. Among
other features, we observed that the ratio between the levels
of expression of pro-apoptotic (BIM) and anti-apoptotic
(BCL-XL and BCL-W) genes was significantly increased.
This result was confirmed with eight additional adenocarci-
noma pancreatic cell lines treated with TSA, suggesting that
a strong determinant for the induction of apoptosis by TSAmay be the consistent increased ratio of expression between
pro-apoptotic and antiapoptotic genes.2. Materials and methods
2.1. Cell culture and RNA extraction
Cells were grown in RPMI 1640 supplemented with 20
mM glutamine and 10% FBS (BioWhittaker Cambrex
Bioscience, Milan, Italy) and were incubated at 37 8C with
5% CO2. TSA was obtained from Sigma Chemical
Company. A 3.3 mM solution of TSA in absolute ethanol
was prepared and stored at 80 8C until use. Cells were
incubated with 0.2 AM TSA for 8 h before harvesting. Total
cellular RNA was prepared using TRIzol Reagent (Invi-
trogen, Milan, Italy) according to the manufacturer’s
instructions.
For quantitative RT-PCR on BCL2L11 (BIM), BCL2L1
(large transcript, Bcl-XL), and BCL2L2 (Bcl-W), the cell
lines CFPAC1, HPAF, MiaPaCa2, Panc1, PC, PSN1, PT-
45P1, PaCa44, and T3M4 were used (see Ref. [27] for
molecular characterization of these cell lines).
2.2. Total cell extract and Western blot analysis
Cells were collected, washed in phosphate-buffered
saline, and resuspended in 0.2 N HCl, 1% h-mercaptoetha-
nol, 1 mM PMSF and 1 protease inhibitor cocktail. After
three cycles of freeze/thaw, the cellular lysate was centri-
fuged at 14,000g for 10 min at 4 8C and the supernatant
was used for Western blot analysis. Protein concentration
was measured using the Bradford protein assay reagent
(Pierce) using bovine serum albumin as a standard. Ten
micrograms of cell protein extracts was electrophoresed
through a 12% SDS-polyacrylamide gel and transferred
onto PVDF membranes (Millipore, Bedford, MA) by
electroblotting. Membranes were then incubated overnight
at 4 8C with blocking solution [5% low-fat milk in TBST
(100 mM Tris, pH 7.5, 0.9% NaCl, 0.1% Tween-20)] and
were probed for 1 h at room temperature with anti-acetyl-
histone H4 polyclonal antibody (Upstate Biotechnology) or
anti-human a-tubulin monoclonal antibody (Oncogene)
(1:1000 in blocking solution). Horseradish peroxidase
conjugated anti-mouse IgG (1:1000 in blocking solution,
Upstate Biotechnology) was used to detect specific proteins.
Immunodetection was carried out using the chemilumines-
cent substrates (Pierce) and recorded by using a Hyper-
filmECL (Amersham Pharmacia Biotech).
2.3. Oligonucleotide array hybridization
First- and second-strand cDNA were synthesized from
12.5 Ag of total RNA according to the manufacturer’s
instructions (Affymetrix, Santa Clara, CA, USA). After in
vitro transcription, labeling and fragmentation, probes were
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probesets, corresponding to about 15,000 genes. The chips
were washed in a GeneChip Fluidics Station 400 (Affyme-
trix), and the results were visualized with a Gene Array
scanner using Affymetrix software.
2.4. Data and statistical analysis
Array data were scaled to achieve a target mean of 100.
The ratios and confidence intervals for each probeset were
determined using the MAS5 statistical algorithm. The
probesets were classified as differentially expressed when
the log2 transformed expression ratio was different from
zero (Pb0.0025) and the probeset was reliably detected
(Pb0.05) in either the treated or untreated samples. Analysis
was performed using Affymetrix MAS 5.0 software.
The probeset annotations were retrieved from NetAffx
analysis center [28]. A set of 4784 sequences was chosen for
cis-regulatory element analysis as they were represented by
single probesets in the HG-U133A Affymetrix Chip,
targeted as present in at least one hybridization and
unambiguously annotated with a unique Ensembl [29] gene
identifier.
The nucleotide sequences of selected loci including 0.5
kb upstream from the transcriptional start site were obtained
by querying the Ensembl database. The presence of
transcription factor binding sites in upstream sequences
was evaluated using MatInspector 2.1 [30] and Transfac 3.1
[31] matrix V$SP1_Q6.
Functional analysis was performed on the basis of Gene
Ontology(GO) terms related to biological function, as
retrieved from the NetAffx Analysis Center.The original
GO terms enclosed with the annotations of each gene
corresponded to terminal nodes of the GO functional
hierarchy. Thus, we enriched the annotations by adding to
each gene, every GO term representing a major class that
included the original ones. Successively, for each GO term
we classified the genes according to two criteria, namely: an
expression change greater then threefold, either as up- or
down-regulation, and the presence of the GO term in their
enriched set of annotations. Thus, we obtained a series of
22 contingency tables representing distributions of genes
with respect to altered expression and membership to GO
functional classes. A Fisher exact test was performed for
each contingency table to find the GO terms that were
significantly over- or underrepresented among the genes
showing altered expression. Only those tests with a P value
less than 0.005 were considered significant. As GO terms
were generally redundant in expressing biological functions,
due to the hierarchical nature of GO database, and most of
the genes fell in more than one category, we focused on a
group of categories which were adequately generic and
possibly not overlapping, in order to represent more
concisely our gene set. Where not otherwise specified, all
calculations were carried out using the R statistical software
package.2.5. Quantitative real-time RT-PCR
Among the highly induced genes, seven were chosen to
validate the array results. These genes were selected because
they were represented by unique Affymetrix probesets, have
no known alternative transcripts, and suitable primers could
be designed for RT-PCR with at least one primer spanning
an exon–exon junction. The software Primer Express 2.0
(Applied Biosystems, Foster City, CA, USA) was used to
design primers.
Quantitative, real-time RT-PCR was performed on three
independent RNA preparations from PaCa44 cells
(untreated or treated with 0.2 AM TSA for 8 h as for
microarray analysis). RNA was extracted as described
above. cDNA first strand synthesis was performed starting
from 1 Ag of total RNA using the AMV First Strand cDNA
Synthesis Kit for RT-PCR (Roche, Basel, Switzerland)
according to the manufacturer’s protocol.
The following primer pairs were used: NGFR (for-
ward: CCTTCAAGAGGTGGAACAGCTG, reverse:
CCACTGTCGCTGTGGAGTTTTT); PGF (forward:
TGTTCAGCCCATCCTGTGTCTC, reverse: CCCA-
GAACGGATCTTTAGGAGC); TNFRSF11A (forward:
ACCCTGGACCAACTGTACCTTC, reverse: TGGT-
GGTTTTCTTAGCTGGCA) ; MFGE8 ( f o rwa rd :
GCTTGCATCTCTTCAGCTGGAA, reverse: ACCT-
GCAGCCACTGATCTTAC); CORO1A ( forward:
GCCTGGAGGTGAACAAGTGTGA , r e v e r s e :
TCCTGGAACAGGTCCGACTTTC); GAPD (forward:
ATCATCAGCAATGCCTCCT, reverse: GGACTGTGGT-
CATGAGTCCT);CDKN1B (forward:CGCTGACTTCATG-
GAATGGAC, reverse: CATCCAACGCTTTTAGAGGCA);
CCNA2 (forward: TCCTCGTGGACTGGTTAGTTGA,
reverse:GCACTGACATGGAAGACAGGAA).
PCRs were performed in 25-Al solution containing 1% of
the reverse transcription product, 10 ng of primers of each
primer and 12.5-Al SYBR Green PCR Master Mix (Applied
Biosystems) and were performed in triplicate. An ABI
PRISM 7000 Sequence Detection System (Applied Biosys-
tems) was used with the following thermal cycle protocol: 94
8C 10min, followed by 40 cycles of 94 8C for 1min and 60 8C
for 1 min. After the run, a dissociation protocol was
performed to ensure the absence of nonspecific products.
The GAPD transcript level was used as a reference.
Quantitative RT-PCR on apoptotic genes was performed
using TaqManR Gene Expression Assays (Applied Bio-
systems), namely Hs00708019_s1 for BCL2L11 (BIM),
Hs00236329_m1 for BCL2L1 (large transcript, Bcl-XL),
Hs00187848_m1 for BCL2L2 (Bcl-W), and Hs_00355782
for CDKN1A (p21) following the manufacturer’s protocol.3. Results
We have previously shown that TSA will inhibit growth
of PaCa44 cells in a dose-dependent manner with an IC50 of
Fig. 2. Comparison of changes in the expression of selected genes by
microarray and quantitative RT-PCR analysis after treatment of PaCa44
cells with TSA. Differences in expression by either technique are as shown.
Gray bars indicate the average of three independent determinations by
quantitative RT-PCR and the standard deviations are also indicated. Black
bars represent the results observed in microarray analysis.
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increase in both apoptosis and the fraction of cells in G2
phase of the cell cycle. To better understand the mechanism
of action of TSA on cellular growth and apoptosis in
PaCa44 cells, we examined the differences in global gene
expression profiles after inhibition of HDACs. For this
purpose, RNAwas isolated from cells that were treated with
0.2 AM TSA for 8 h. This time was chosen in order to give a
high level of histone H4 acetylation as determined by
Western blot analysis of three pancreatic cancer cell lines
(Fig. 1) and to observe the most direct effects of TSA on
gene expression [32]. RNA from TSA-treated and untreated
cells was subjected to analysis using Affymetrix U133A
gene chips, and the resulting gene expressions profiles were
compared. After prefiltering to eliminate data points that
were scored as absent in both treated and untreated samples,
a total of 13,413 detectable spots remained, representing
about 9000 genes. The complete data set is available as
supplementary material.
To verify the results of the microarray analysis,
quantitative real-time RT-PCR was performed on seven
randomly chosen genes among those scored as differentially
expressed. As shown in Fig. 2, the fold change in these
seven genes was similar to that found by microarray
analysis, indicating the validity of the results. Fig. 3A
shows a distribution of mRNA expression on the basis of
the ratio of expression in the TSA-treated and untreated
samples, while the data are presented numerically in Fig.
3B. TSA induced both the induction and repression of a
large number of genes. However, the number of probesets
whose expression was up-regulated was greater than the
number of probesets that were down-regulated, especially
when higher threshold values were considered (Fig. 3A and
B). When a threshold value of 3 was used as a cutoff level
for differential expression, a total of 306 genes (correspond-
ing to 346 probesets) had altered expression, representing
3.4% of detectable genes. Of these, 59 were down-regulated
while 247 were up-regulated. The 60 most interesting genes,
selected on the basis of those playing a known or deducedFig. 1. Western blot analysis of histone acetylation following treatment of
various cell lines with TSA at different times. Cells were treated as
described in the Materials and methods.role in cellular proliferation/apoptosis/cell-cycle control, are
shown in Table 1.
The genes with altered expression after treatment with
TSA were subsequently classified according to cellular
function. The Gene Ontology categories that most summar-Fig. 3. Distribution of differentially expressed genes after treatment of
PaCa44 cells with TSA. (A) Histogram representation. The number of
probesets showing altered expression is plotted against the difference in the
ratio of expression. The black area shows probesets scored as differentially
expressed genes by MAS5 software. The gray area represents the
distribution of all probesets. (B) Number of differentially expressed
probesets at selected cutoff values.
Table 1
60 Most interesting differentially expressed genes after treatment with TSA
Gene description Gene symbol Fold change
(log2)
A disintegrin and
metalloproteinase
domain 19 (meltrin beta)
ADAM19 2.1
BCL2-like 1 BCL2L1 1.8
BCL2-like 11
(apoptosis facilitator)
BCL2L11 3.4
BCL2-like 2 BCL2L2 0.6
BTB and CNC homology 1,
basic leucine zipper
transcription factor 2
BACH2 1.8
Ca2+-promoted Ras inactivator CAPRI 3.7
Colon cancer-associated
protein Mic1
MIC1 1.7
Cyclin A2 CCNA2 1
Cyclin-dependent kinase
(CDC2-like) 10
CDK10 1.2
Cyclin-dependent kinase
inhibitor 1A (p21, Cip1)
CDKN1A 1.6
Cyclin-dependent kinase
inhibitor 1B (p27, Kip1)
CDKN1B 0.9
Cyclin-dependent kinase
inhibitor 1C (p57, Kip2)
CDKN1C 1
Cyclin-dependent kinase
inhibitor 2D (p19,
inhibits CDK4)
CDKN2D 1.8
DNA (cytosine-5-)-
methyltransferase 3 beta
DNMT3B 1.9
Dual-specificity tyrosine-
(Y)-phosphorylation
regulated kinase 3
DYRK3 1.6
Fas apoptotic inhibitory
molecule
FAIM 1.6
G protein-coupled receptor 39 GPR39 1.7
G protein-coupled receptor 87 GPR87 1.8
G protein-coupled
receptor kinase 5
GPRK5 3.8
GATA binding protein 3 GATA3 5.5
GTP binding protein
overexpressed in
skeletal muscle
GEM 1.8
Hairy/enhancer-of-split related
with YRPW motif 1
HEY1 1.6
Histone deacetylase 7A HDAC7A 2.2
Histone deacetylase 9 HDAC9 1.8
Inhibitor of DNA binding 2,
dominant negative
helix-loop-helix protein
ID2 1.6
Katanin p80 (WD40-
containing) subunit B1
KATNB1 2.1
MAD, mothers against
decapentaplegic homolog
1 (Drosophila)
MADH1 1.6
MAP kinase-interacting serine/
threonine kinase 2
MKNK2 1.6
MAX interacting protein 1 MXI1 2.1
msh homeo box homolog 2
(Drosophila)
MSX2 1.9
myc-induced nuclear antigen,
53 kDa
MINA53 1.6
Notch homolog 1,
translocation-associated
(Drosophila)
NOTCH1 2
Table1 (continued)
Gene description Gene symbol Fold change
(log2)
Nuclear receptor coactivator 2 NCOA2 1.9
Nuclear receptor coactivator 3 NCOA3 1.6
Nuclear receptor interacting
protein 1
NRIP1 1.6
Phosphatidylinositol
4-kinase type II
PI4KII 1.8
Phosphoinositide-3-kinase,
catalytic, delta polypeptide
PIK3CD 1.8
Protein kinase C binding
protein 1
PRKCBP1 3.9
Protein kinase, cAMP-
dependent, regulatory,
type II, beta
PRKAR2B 2.3
Protein phosphatase 2,
regulatory subunit B
(B56), beta isoform
PPP2R5B 1.6
RAB3A, member RAS
oncogene family
RAB3A 3
RAB40B, member RAS
oncogene family
RAB40B 3.3
RalGDS-like gene RGL 2.6
Ras and Rab interactor 2 RIN2 1.8
RAS guanyl releasing protein 2
(calcium and
DAG-regulated)
RASGRP2 2.9
Ras-induced senescence 1 RIS1 3.3
Ras-like protein TC10 TC10 2.2
Signal transducer and activator
of transcription 1, 91 kDa
STAT1 0.5
Single-stranded DNA binding
protein 2
SSBP2 2.5
Snail homolog 2 (Drosophila) SNAI2 1.7
SWI/SNF related, matrix
associated, subfamily a,
member 2
SMARCA2 4.5
Transforming growth factor,
beta receptor II (70/80kDa)
TGFBR2 0.7
Tumor necrosis factor (ligand)
superfamily, member 9
TNFSF9 2.2
Tumor necrosis factor receptor
superfamily, member 10b
TNFRSF10B 0.9
Tumor necrosis factor receptor
superfamily, member 10b
TNFRSF10B 0.9
Tumor necrosis factor receptor
superfamily, member 1B
TNFRSF1B 3.9
Tumor necrosis factor receptor
superfamily, member 25
TNFRSF25 1.7
Tumor necrosis factor receptor
superfamily, member 9
TNFRSF9 0.7
zinc finger protein 161
homolog (mouse)
ZFP161 1.8
zinc finger protein, X-linked ZFX 2.1
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along with their gene abundance in Table 2.
Since at least a major part of the effects of TSA can be
ascribed to induction of apoptosis, we chose to further
analyze the expression of key apoptotic genes with altered
expression by microarray analysis in eight additional
pancreatic cancer cell lines by quantitative RT-PCR that we
have previously characterized for growth inhibition by TSA
Table 2
Functional classification of genes showing altered expression after treat-
ment with TSA
Functional category Number
of genesb
OR Pa Total number
of genes
Metabolism 94 0.61 0.001 2995
Cell–cell signaling 17 2.63 0.001 187
Cell cycle 7 0.41 0.015 413
Development 33 1.57 0.030 589
Ion transport 12 1.57 0.139 206
Regulation of transcription 21 0.73 0.206 704
Cell proliferation 9 1.11 0.710 210
Signal transduction 45 1.20 0.315 1016
Vesicle-mediated transport 7 1.13 0.678 161
Chromosome organization
and biogenesis
5 1.08 0.809 120
Cell motility 5 0.86 1.000 148
a Fisher’s exact test.
b Based on a cutoff value of 3.0.
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significantly up-regulated by TSA in all cell lines tested,
while Bcl-XL and Bcl-W showed significant down-regula-
tion. To obtain more information on how the levels of histone
acetylation influence gene expression, a time course experi-
ment was performed in which the expression of selected
apoptosis and cell cycle related genes was monitored at
various times after treatment with TSA. These results
demonstrate that the expression of the genes analyzed
generally shows maximal alteration within 8 h (Fig. 5), a
time that coincides with the maximal effects on histone
acetylation observed in Western blot analysis (Fig. 1).
It has been previously suggested that the transcriptional
factors belonging to the Sp1 family may play a role in
alteration of gene expression after inhibition of HDAC [33–
36]. To further explore this possibility, we determined the
presence and number of Sp1 (GC-box) binding sites within
500 bp of the transcriptional initiation site of genes that
showed altered expression after treatment with TSA (Table
3). It was found that Sp1 sites were significantly more
abundant among induced genes (14%) with respect to those
that were not differentially expressed (7%) or down-
regulated (6%) (Pb0.001). The distribution of the binding
sites for the transcription factor NF-nB was not significantly
different among promoters of genes showing differential
expression after TSA treatment (data not shown).Fig. 4. The plot represents expression changes of apoptosis related genes
(BCL-XL, BCL-W and BIM), in various pancreatic cell lines, following
treatment with TSA 0.2 AM after 8 h. Each bar corresponds to the base-two
logarithm of gene expression ratio between treated and untreated samples,
normalized using GAPD transcript levels. The means and S.E. are obtained
using three replicates.4. Discussion
The interest in the use of inhibitors of HDAC stems from
the fact that they induce apoptosis as well as chromatin
remodeling, which may be responsible for the observed
antitumor effects. Clinically, HDAC inhibitors have shown
promise only in hematologic malignancies, although their
possible application to solid tumors, including pancreatic
cancer, has nonetheless been demonstrated in vitro. The
development of additional molecules that alter the equili-brium of histone acetylation would benefit from a greater
understanding of the molecular mechanism of action and the
pathways involved. The present work addresses this issue
by examining the global gene expression patterns induced in
pancreatic cancer cells by microarray analysis after treat-
ment with TSA, a well-known HDAC inhibitor.
Our data add support to the concept that TSA does not
have global effects on gene expression, but rather alters the
expression of a relatively small number of specific genes.
Among those with known or deduced cellular function, the
differentially expressed genes were found to be involved in
a wide variety of cellular processes, including cell prolif-
eration, signaling, regulation of transcription, and apoptosis.
Lastly, on a genomic scale, we showed that there was a
significant correlation between the presence of a binding site
for the transcription factor Sp1 and the probability of
induction by TSA.
Previous investigations into the gene alterations caused
by TSA have reported widely varying percentages (from 1–
7%) with regards to the number of total genes that are
differentially expressed after treatment by this inhibitor of
HDAC [37]. While in part these apparent discrepancies can
be explained by the different methodologies used, the
reported differences may also be explicable by the different
treatment times with TSA. In the present study, considering
a threshold value of 3.0 as significant for differentially
expressed genes, a total of 3.4% of genes showed altered
expression after treatment with TSA, a value consistent with
the range found from previous studies.
To our knowledge, this is the first functional classifica-
tion of differentially expressed genes following TSA treat-
ment. Not unsurprisingly, TSA caused the up- and down-
regulation of numerous genes involved in a wide variety of
cellular processes. The categories of metabolism and cell–
cell signaling were underrepresented, although the signifi-
cance of this is unclear at present.
Only a limited number of studies have analyzed the
effects of TSA on gene expression by microarray analysis
Fig. 5. Time-dependent effects of TSA on the expression of selected genes as determined by quantitative RT-PCR. The base-two logarithm of gene expression
ratio between untreated and samples treated for various times is shown. Samples were normalized using GAPD transcript levels as a reference. Empty triangles,
PT45; solid squares, PaCa44; empty squares, T3M4.
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[22,24–26]. Regarding pancreatic cancer, only a single
study has been reported on the gene expression profile after
treatment with TSA [25]. However, in that report, TSA was
used as an agent to allow for gene reexpression, before
treatment with a demethylating agent, in order to screen for
targets of aberrant methylation; the most direct effects of
TSA on gene expression after a relatively short treatment
period, i.e., about 8 h, were not examined. We observed that
maximal levels of gene expression occurred at 8 h following
TSA treatment, while its effects were less evident at earlier
or later time points, depending on the gene under
examination (Fig. 5). These results correlate well with the
levels of histone acetylation observed by Western blot
analysis (Fig. 1). Interestingly, a recent study has attemptedTable 3
Distribution of GC-boxes in the proximal promoter region
Number/presence of GC-boxesa
Absent Present 1 2 N2
Up-regulated 682 113 94 14 5
Down-regulated 699 44 42 2 0
No change 3090 219 184 31 4
Differential expression tag determined by the MAS5 algorithm.
a Occurrence of GC-box within 500 bp of the transcriptional initiation
site.to define a common gene set, consisting of eight up-
regulated and five down-regulated genes, which were all
altered by HDAC inhibition from analysis of bladder and
breast cancer cell lines [22]. Considering this set of 13
genes, all were up- or down-regulated, although to different
extents, in our present analysis of a pancreatic cancer cell
line (data not shown). This group of commonly altered
genes included p21, histone H2B, TRPM-2, and the
transformation-related protein TRP [22].
Additionally, we found that Sp1/Sp3 sites were signifi-
cantly more abundant among TSA-induced genes with
respect to either uninduced or down-regulated genes. This
provides further confirmation of the activating role on
transcription that these cis-acting elements play upon
treatment with TSA. In fact, Sp1/Sp3 transcription factor
binding sites have been frequently implicated in changes in
gene expression following alterations in chromatin acetyla-
tion [38,39]. In particular, Sp1/Sp3 binding sites situated in
the proximity of the transcription start site have been
reported as necessary for the TSA induction of the p21
promoter [40]. A repressor function has also been attributed
to the Sp1/Sp3 family of transcription factors due to their
ability to form repressor complexes with HDACs [41,42].
Moreover, it has been suggested that an increase in the
acetylation status of Sp3 induced by TSA may cause a
switch from a repressor to an activator function, leading to
P.S. Moore et al. / Biochimica et Biophysica Acta 1693 (2004) 167–176174an increased expression of genes with receptive binding
sites [43]. Thus, the greater abundance observed of Sp1
motifs in the genes up-regulated by TSA may be explained
by either changes in the posttranslational acetylation status
of GC-box binding transcription factors or the impairing of
a repressor complex activity due to inactivation of HDACs.
We have previously shown that TSA arrests cellular
growth in G2 and induces apoptosis in pancreatic cancer cell
lines [14]. With regard to the former phenomenon, the
cyclin-dependent kinase inhibitors p21 (CDKN1A), p19
(CDKN2D), and p57 (CDKN1C) have been previously
associated with cell growth arrest in G2 phase [44–47]. All
three genes were up-regulated after treatment with TSA. In
addition, cyclin A (CCNA2) and cdk10 (CDK10), modu-
lators of progression from G2 to M [48,49], were down-
regulated. Thus, the change in expression of these genes is
highly consistent with the observed growth arrest in G2
caused by TSA in pancreatic cancer cell lines [14].
Consistent with the apoptotic effects of TSA on
pancreatic cancer cells [14], we observed the up- and
down-regulation of genes involved in apoptotic cell death,
in both the mitochondrial and the death receptor pathways.
Interestingly, BIM (BCL2L11), a proapoptotic BH3-only
BCL-2 family member [50,51], showed significant induc-
tion by TSA, in both microarray analysis and RT-PCR of
pancreatic cancer cell lines. The BH3 domain is a nine-
amino-acid region required in the binding of Bcl-2-like pro-
survival proteins, and participates in the initiation of
apoptosis through the mitochondrial pathway. It has been
recently demonstrated that transient transfection of BIM in
NIH 3T3 mouse fibroblasts determines apoptotic cell death,
which can be blocked by overexpression of Bcl-2 [51].
Moreover, we demonstrated that TSA represses the expres-
sion of the antiapoptotic genes BCL-XL (BCL2L2) and
BCL-W (BCL2L1). It has been previously reported that
treatment with antisense oligonucleotide for these antiapop-
totic genes induced apoptotic cell death [52–54]. Thus, our
data on the consistent alteration of expression of BIM, BCL-
XL, and BCL-W in all nine pancreatic cancer cell lines
tested suggest that the increased ratio between the levels of
expression of pro-apoptotic and anti-apoptotic genes may be
a strong determinant for the induction of apoptosis by TSA.
In pancreatic cancer, the enhanced expression of BCL-XL
may be associated with decreased survival [55], and
resistance to chemotherapy may be at least partly mediated
by this gene [56]. Furthermore, in pancreatic cancer cells,
the ratio between the levels of expression of pro-apoptotic
and anti-apoptotic genes is predictive of sensitivity towards
cytotoxic drugs [57,58]. Thus, our results suggest that
pancreatic cancer treatment with TSA may enhance its
sensitivity towards chemotherapy.
A second group of related genes involved in apoptotic
signaling by TNF were also induced by TSA, namely the
TNF ligand TNFSF9 and the TNF receptor members
TNFRSF10D, TNFRSF10B and TNFRSF9. It has been
amply demonstrated that TNF is able to kill cells throughapoptosis by a mechanism that involves signaling by the
death receptor family to which the TNF receptor belongs
[59,60]. This is in agreement with the observation that
HDAC inhibitors sensitize some cancer cells to TNF-related
apoptosis-inducing ligand (TRAIL)-induced apoptosis [61].
More recent studies have shown that NF-nB, a transcription
factor activated upon TNF signaling, is partly responsible
for masking the apoptotic effect of TNF [59], in agreement
with the observation that NF-nB prevents cells from
undergoing apoptosis. In contrast, the induction of another
transcription factor, STAT-1, has been found to play a key
role in TNF-mediated apoptotic cell death [62]. Since our
data show that TSA represses the gene for the p105
precursor of p50 NF-nB and activates the STAT1 gene, it
may be that the up-regulation of TNF and its receptor by
TSA may represent additional factors that contribute to the
apoptotic cell death induced by TSA.
In summary, with specific regards to the biological
effects of TSA in pancreatic cancer cells, namely the block
of cell growth in G2 and induction of apoptosis, expression
profiling after treatment with TSA identified several genes
that may be related to this phenomena. These include
several cyclin-dependent kinase inhibitors, members of the
BCL family, and genes involved in apoptotic signaling by
TNF that at least in part may be responsible for the observed
effects of TSA on cellular growth.Acknowledgements
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